

# Ping An (2318 HK/601318 CH)

## 1Q OPAT a slight beat; positive outlook for full-year NBV and life OPAT acceleration

Ping An posted solid 1Q26 results, with Group OPAT up 7.6% YoY to RMB40.8bn, outpacing our estimate of RMB39.2bn ([link](#)). This increase can be attributed to 1) a resilient L&H OPAT uptrend (+4.6% vs. CMBI est: +4.5%); 2) PAB profit turnaround (+3.0%); and 3) a notable surge in AM profitability (+193.3%). Group NPAT fell 7.4% YoY to RMB25bn, slightly better than our estimate of RMB24.3bn, due to heightened market headwinds in 1Q26. Group net asset value (NAV) grew 1.8% from year-start to RMB1.02tn, in line with our forecast. Life NBV grew 20.8% YoY to RMB15.6bn (vs. CMBI est: RMB15.4bn), mainly driven by new business sales (+45.5% YoY) partially offset by a softening margin (-4.8pct YoY). P&C UW performance was a beat, with COR down 0.8pct YoY to 95.8% and non-auto premium rising 19.5% YoY, which exceeded the industry average growth of 5.3% YoY in 1Q26. **Mgmt. mentioned in the call that achieving double-digit NBV growth in 2026E is a baseline target, and we are positive on a high-teens NBV uptick and life OPAT acceleration in 2026E as CSM approaches an inflection point.** Maintain BUY, with our SOTP-based H/A-share TP at HK\$86/RMB75, implying 0.83x FY26E P/EV.

■ **1Q OPAT a slight beat, driven by L&H/PAB/AM.** Group OPAT growth in 1Q26 was mainly driven by increases in Life & Health (+4.6%), Ping An Bank (+3.0%) and AM (+193.3%). L&H OPAT growth was broadly in line with our forecast, with new business CSM likely to achieve a promising rise amid stable interest rates. The banking business returned to positive growth, driven by 1) a stabilized NIM (1Q26: 1.79% vs. FY25: 1.78%), and 2) non-interest income growth from wealth management and bond investments. AM OPAT amounted to RMB3.2bn in 1Q26, nearly tripling from 1Q25, thanks to upside from brokerage and asset management businesses amid heightened equity volatility which bolstered trading activity. **We maintain our view that continued easing of the AM drag and expected Life OPAT acceleration should drive a re-rating over time.**

■ **L&H OPAT in-line; NBV rose on higher new business sales.** Life NBV grew 20.8% YoY to RMB15.6bn, driven by strong new policy sales (+45.5%) partially offset by a 4.8pct YoY decline in margin to 23.5%. Mgmt. noted that this margin contraction was not due to product or channel skewness, but rather the fact that the comparable 1Q25 figures were not adjusted for changes in actuarial assumptions. Overall, NBV margin stood stable vs. the year-start level of 23.4%. Bancassurance was the leading channel for NBV growth, with its contribution (together with community finance) rising 6.8pct YoY to ~31% in 1Q26. Agent headcount declined 5.4% from year-start to 0.33mn, partly due to seasonality. We expect NBV to reach high-teens YoY growth in 2026E led by new business sales.

■ **P&C underwriting beat; OPAT weighed by investment.** P&C COR improved 0.8pct YoY to 95.8% in 1Q26, better than our estimate of 96.1%, due to lower NAT CAT claims and continued expense rate controls across non-auto insurance lines. Total premium rose 6.8% YoY to RMB91bn, with auto insurance down 0.6% YoY to RMB53bn, and non-auto up 19.5% YoY to RMB38bn in 1Q26. Per mgmt., non-auto premium growth was mainly driven by health insurance. UW profit grew 28.4% YoY to RMB3.5bn, but this was partially offset by a decline in investment return, resulting in a 13.4% YoY decrease in P&C OPAT in 1Q26.

■ **Stable NIY; CIY recorded a larger decline.** In 1Q26, NIY was broadly stable at 0.8% (unannualized) vs. 0.9% in 1Q25, boding well for a stabilized trend in market interest rate. CIY posted a larger decline of 1.1pct YoY to 0.2% (unannualized), mainly due to heightened equity market headwinds in 1Q. Total investment assets remained stable at ~RMB6.55tn, up 0.9% from year-start.

■ **Maintain BUY with TP of HK\$86/RMB75.** The stock is now trading at 0.6x FY26E P/EV and 0.8x FY26E P/B. We are positive on the prospect of Ping An's core business improvement, including 1) Life OPAT acceleration in 2026E as CSM approaches the inflection; 2) PAB profit enhancement; and 3) ongoing progress on AM de-risking. Maintain BUY with our TP at HK\$86 (H-share, unchanged) and RMB75 (A-share, added), implying 0.83x FY26E P/EV and 1.2x FY26E P/B.

	2318 HK	601318 CH
	BUY	BUY
	Maintain	Maintain
TP	HK\$86.0	RMB75.0
Prior TP	HK\$86.0	RMB75.0
Up/Downsid	43.2%	30.1%
Current Pric	HK\$60.1	RMB57.6



### China Insurance

#### Nika MA

(852) 3900 0805

nikama@cmbi.com.hk

#### 12-mth Price Performance



Source: FactSet

### Share performance

	2318.HK		601318.CH	
	Abs.	Rel.	Abs.	Rel.
1-mth	1.3%	-1.6%	1.2%	-4.4%
3-mth	-15.4%	-8.3%	-11.0%	-16.3%
6-mth	6.9%	9.7%	-0.2%	5.2%

Source: Factset

### Stock data

(LC)	2318.HK	601318.CH
Mkt Cap (bn)	1,087.4	1,043.6
Avg. 3mths t/o (mn)	2,553.40	4,752.95
52w High	73.45	74.32
52w Low	45.60	50.71
Issued Shares (mn)	18,108	18,108

### Auditor: Ernst & Young

#### Related reports:

- [1Q26 preview: Expect resilient OPAT, NPAT to slide on equity swings; solid NBV uptrend](#), Apr 22, 2026
- [Group OPAT back to double-digit rise; expect CSM to return to positive growth in 2026E](#), Mar 30, 2026
- [Banca fuelling NBV growth in jumpstart sales; 4Q earnings could ease on growth stock corrections](#), 23 Jan 2026
- [China Insurance - Easing solvency risk factors to steer insurance funds into long-term stockholdings](#), 8 Dec 2025
- [3Q earnings beat: improving business quality with catalysts across-the-board worth to expect](#), 31 Oct, 2025
- [1H25 a mixed bag: NBV beat while OPAT in line](#), Aug 28, 2025

## Earnings Summary

(YE 31 Dec)	FY24A	FY25A	FY26E	FY27E	FY28E
EPS (Reported)(RMB)	7.16	7.68	8.20	8.72	9.44
Consensus EPS (RMB)	n.a	n.a	8.03	8.53	8.94
P/B (x)	1.0	1.0	0.8	0.8	0.7
P/Embedded value (x)	0.7	0.6	0.6	0.6	0.5
Dividend yield (%)	4.9	5.3	5.5	5.8	6.2

Source: Company data, Bloomberg, CMBIGM estimates

- **Catalysts:** 1) expected Life CSM release and balance growth inflection in 2026E; 2) continued AM OPAT outperformance led by faster-than-expected de-risking progress; 3) accelerating OPAT payout ratio growth; 4) significant rallies in equity markets; 5) new protection-typed product rollouts, i.e. participating critical illness.
- **Key risks:** 1) regulatory tightening on life insurance and financial conglomerates; 2) heightened equity market volatility; 3) prolonged low-interest rate environment; 4) intensified pricing competition in P&C industry; 5) asset quality deterioration; and 6) a significant decline in Group capital level weighing on DPS growth, etc.
- **Ping An-H (2318 HK):** We derive our price target of HK\$86 for Ping An-H (2318 HK) based on SOTP, assuming a 12.5% cost of capital and 2.5% terminal growth rate. Our valuation includes 1) 1.3x Life EV, based on ~13% average ROEV in FY26-28E; 2) 0.9x book value (BV) for Ping An P&C; 3) 0.6x BV for PAB; 4) 1.0x BV for AM and other segments; 5) HK\$0.8 per share for finance enablement businesses based on P/B-ROE; and 6) a 15% Group conglomerate discount. Our TP implies 0.83x FY26E P/EV and 1.2x FY26E P/B, vs. currently trading at 0.6x FY26E P/EV and 0.8x FY26E P/B.
- **Ping An-A (601318 HK):** We derive our price target of RMB75 for Ping An-A (601318 CH) based on SOTP and by applying a CNY/HKD exchange rate of 1.09 and an H/A discount of 7%, referring to an average of year-to-date trading. Our TP implies 0.83x FY26E P/EV and 1.2x FY26E P/B, vs. currently trading at 0.6x FY26E P/EV and 0.9x FY26E P/B.
- **Investment thesis:** Ping An is in the advanced phase of de-risking its property exposure, and with consecutive provisions being made for the AM segment, we expect the AM drag to ease further, which could drive the Group's valuation re-rating over time. As of FY25, the operating loss from AM segment narrowed significantly to RMB3.8bn from RMB11.9bn in the prior year. We believe continued improvement in its core business performance should support a share price re-rating, alongside mgmt.'s focus on shareholder returns and an enhanced balance sheet. We like Ping An for its resilient growth recovery driven by 1) Life OPAT growth acceleration in 2026E, as CSM release approaches an inflection point; 2) continued progress on AM de-risking; and 3) an advanced deployment in technology and the buildout of a healthcare and elderly care ecosystem. We see Ping An as a pioneer in life insurance reform, and expect intra-Group cooperation to further drive synergies and operational efficiency.
- **Company description:** Founded in 1988, Ping An is a leading financial conglomerate with businesses spanning life and P&C insurance, pension, banking, brokerage, trust, and other financial services. The company pursues a technology-empowered growth strategy across core financial businesses of insurance, banking, brokerage, and asset management. As of FY25, Ping An ranked as the second-largest Life and P&C insurers in China by total written premiums. The banking business segment is operated by its subsidiary Ping An Bank (000001 CH, 58% Group stake), which has a focus on retail and SME businesses. Ping An Healthcare and Technology (1833 HK, 53% Group stake) was listed in May 2018 as China's first listed internet-health company.

## Financial Summary

INCOME STATEMENT	2023A	2024A	2025A	2026E	2027E	2028E
<b>YE 31 Dec (RMB mn)</b>						
Insurance revenue	536,440	551,186	559,502	570,712	594,017	626,469
Insurance service expenses	(440,178)	(449,102)	(453,268)	(463,856)	(483,459)	(510,215)
Net expenses from reinsurance contracts held	(3,731)	(3,601)	(5,066)	(5,286)	(5,518)	(5,824)
<b>Insurance service results</b>	<b>92,301</b>	<b>98,127</b>	<b>100,970</b>	<b>101,791</b>	<b>105,271</b>	<b>110,674</b>
Net finance (expenses)/income from insurance contracts	(123,959)	(172,662)	(179,978)	(202,519)	(227,180)	(255,861)
Net finance (expenses)/income from reinsurance contracts	542	960	336	339	359	384
Interest income	118,503	123,627	135,798	151,689	168,444	187,650
Net investment income	33,324	161,074	154,544	163,491	181,256	201,740
Other gains/(losses) from changes in fair value	(9,940)	(19,814)	(13,795)	(12,435)	(13,784)	(13,928)
<b>Net investment results</b>	<b>18,470</b>	<b>93,185</b>	<b>96,905</b>	<b>100,566</b>	<b>109,095</b>	<b>119,986</b>
Net interest income from banking operations	118,947	93,913	88,662	86,134	83,663	80,997
Net interest income/(expenses) from non-banking operations	(24,346)	(19,405)	(20,533)	(20,397)	(21,191)	(22,924)
Loan loss provisions	(62,833)	(56,245)	(54,738)	(53,326)	(52,247)	(50,887)
Other fee and commission income/(expenses)	(8,773)	(7,841)	(9,779)	(9,610)	(9,518)	(9,429)
Other income	68,804	65,191	73,345	80,126	88,429	98,548
Other expenses	(129,813)	(139,117)	(137,291)	(145,142)	(153,609)	(164,106)
Foreign exchange gains/losses	120	380	618	618	618	618
<b>Other results</b>	<b>7,912</b>	<b>(17,338)</b>	<b>(7,481)</b>	<b>(8,178)</b>	<b>(9,188)</b>	<b>(11,204)</b>
<b>Profit before tax</b>	<b>120,117</b>	<b>170,495</b>	<b>185,590</b>	<b>189,344</b>	<b>200,226</b>	<b>214,306</b>
Income taxes	(10,843)	(23,762)	(27,289)	(27,216)	(28,543)	(29,737)
<b>Net profit</b>	<b>109,274</b>	<b>146,733</b>	<b>158,301</b>	<b>162,128</b>	<b>171,683</b>	<b>184,569</b>
<b>Net profit attributable to shareholders</b>	<b>85,665</b>	<b>126,607</b>	<b>134,778</b>	<b>144,001</b>	<b>153,056</b>	<b>165,744</b>

BALANCE SHEET	2023A	2024A	2025A	2026E	2027E	2028E
<b>YE 31 Dec (RMB mn)</b>						
<b>ASSETS</b>						
Cash and amount due from banks and other financial institutions	804,077	1,018,027	1,189,867	1,268,310	1,355,602	1,402,775
Balances with central bank and statutory deposits	329,531	344,608	334,290	338,552	342,868	345,047
Intangible assets	99,078	97,263	83,478	59,290	42,110	35,489
Investments in associates and joint ventures	258,877	185,514	141,251	144,090	146,986	148,456
Property	50,401	48,603	46,934	47,032	47,131	47,180
Investment property	121,406	119,158	128,259	141,158	155,926	164,094
Reinsurance contract assets	22,215	26,084	25,515	28,689	31,552	33,079
Loans and advances to customers	3,320,110	3,294,053	3,320,386	3,378,649	3,459,909	3,525,498
Fixed maturity investments	4,976,779	5,912,846	6,074,144	6,705,605	7,429,889	7,831,064
Equity investments	1,130,853	1,328,664	1,928,348	2,142,865	2,389,790	2,526,941
Derivative financial assets	44,978	68,698	30,002	33,077	36,468	38,291
Deferred tax assets	101,337	122,012	114,640	90,270	71,081	63,075
Other assets	323,775	392,297	481,357	2,125,429	1,700,069	1,535,590
<b>Total assets</b>	<b>11,583,417</b>	<b>12,957,827</b>	<b>13,898,471</b>	<b>16,503,016</b>	<b>17,209,380</b>	<b>17,696,579</b>
<b>LIABILITIES</b>						
Due to banks and other financial institutes	963,718	838,183	1,104,609	972,826	1,021,468	1,133,064
Customer deposits and payables to brokerage customers	3,534,539	3,710,167	3,809,246	6,044,885	6,166,387	6,228,051
Insurance contract liabilities	4,159,801	4,984,795	5,360,910	5,903,488	6,492,648	6,806,826
Obligations under repurchase agreements	241,803	462,292	643,547	521,273	422,231	342,007
Derivative financial instruments	44,531	74,937	46,862	47,804	48,765	49,252
Deferred tax liabilities	14,148	13,977	6,647	3,739	2,103	1,577
Current tax liabilities	7,117	14,970	11,095	7,101	4,545	3,636
Other liabilities	1,388,743	1,553,225	1,499,030	1,410,437	1,327,080	1,325,269
<b>Total liabilities</b>	<b>10,354,453</b>	<b>11,653,115</b>	<b>12,482,483</b>	<b>14,911,554</b>	<b>15,485,227</b>	<b>15,889,683</b>
<b>EQUITIES</b>						
Share capital	18,210	18,210	18,108	18,108	18,108	18,108
Reserves	263,752	221,594	215,070	260,348	253,733	249,945
Retained profits	622,050	693,797	767,241	862,540	964,020	1,030,463
<b>Total shareholders' equity</b>	<b>899,011</b>	<b>928,600</b>	<b>1,000,419</b>	<b>1,140,997</b>	<b>1,235,861</b>	<b>1,298,516</b>
Non-controlling interests	329,953	376,112	415,569	450,465	488,292	508,381
<b>Total equity</b>	<b>1,228,964</b>	<b>1,304,712</b>	<b>1,415,988</b>	<b>1,591,462</b>	<b>1,724,153</b>	<b>1,806,896</b>
<b>Total liabilities &amp; equity</b>	<b>11,583,417</b>	<b>12,957,827</b>	<b>13,898,471</b>	<b>16,503,016</b>	<b>17,209,380</b>	<b>17,696,579</b>

PER SHARE DATA	2023A	2024A	2025A	2026E	2027E	2028E
<b>YE 31 Dec</b>						
DPS (RMB)	2.48	2.61	2.78	2.92	3.09	3.28
EPS (Reported, RMB)	4.84	7.16	7.68	8.20	8.72	9.44
Consensus EPS (RMB)	n.a	n.a	n.a	8.03	8.53	8.94
No. of shares basic (mn)	18,210	18,210	18,108	18,108	18,108	18,108
PROFITABILITY	2023A	2024A	2025A	2026E	2027E	2028E
<b>YE 31 Dec</b>						
Return on equity (ROE)	9.7%	13.9%	14.0%	13.4%	12.0%	13.0%
Operating ROEV	7.7%	7.5%	7.4%	6.9%	7.2%	7.5%
VNB margin (FYP basis)	23.7%	18.5%	23.4%	24.4%	25.4%	26.5%
Combined ratio (%)	100.7%	98.3%	96.8%	96.8%	96.7%	96.6%
VALUATION	2023A	2024A	2025A	2026E	2027E	2028E
<b>YE 31 Dec</b>						
P/Embedded value (x)	0.7	0.7	0.6	0.6	0.6	0.5
P/B (x)	1.1	1.0	1.0	0.8	0.8	0.7
Dividend yield (%)	4.7	4.9	5.3	5.5	5.8	6.2
Dividend payout (%)	51.4	36.5	36.3	35.6	35.5	34.8

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

# Disclosures & Disclaimers

## Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## CMBIGM Ratings

**BUY** : Stock with potential return of over 15% over next 12 months  
**HOLD** : Stock with potential return of +15% to -10% over next 12 months  
**SELL** : Stock with potential loss of over 10% over next 12 months  
**NOT RATED** : Stock is not rated by CMBIGM

**OUTPERFORM** : Industry expected to outperform the relevant broad market benchmark over next 12 months  
**MARKET-PERFORM** : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months  
**UNDERPERFORM** : Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

**Address:** 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

**CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)**

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.